Aprea Therapeutics Inc logo

APRE - Aprea Therapeutics Inc News Story

$4.3 0.0  0.9%

Last Trade - 07/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £65.2m
Enterprise Value £1.49m
Revenue £n/a
Position in Universe 5228th / 6858

BRIEF-Aprea Therapeutics Receives FDA Orphan Drug Designation For Eprenetapopt For The Treatment Of Acute Myeloid Leukemia

Thu 8th April, 2021 5:04pm
April 8 (Reuters) - Aprea Therapeutics Inc  APRE.O :
    * APREA THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION
FOR
EPRENETAPOPT FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)

Source text for Eikon:  urn:newsml:reuters.com:*:nGNX9HqlTj
Further company coverage:  APRE.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.